Early Results of Prostate Cancer Drug Clinical Trial Appear Encouraging, Nymox Says
News
Nymox Pharmaceutical Corp. recently announced the 18-month results from its 40-month Phase 2 clinical trial (NX03-0040) of fexapotide triflutate (NX-1207) in localized prostate cancer. The results revealed the study endpoints were met and ... Read more